A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

R. Hájek*, T. Masszi, M. T. Petrucci, A. Palumbo, L. Rosiñol, A. Nagler, K. L. Yong, A. Oriol, J. Minarik, L. Pour, M. A. Dimopoulos, V. Maisnar, D. Rossi, H. Kasparu, J. Van Droogenbroeck, D. B. Yehuda, I. Hardan, M. Jenner, M. Calbecka, M. DávidJ. De La Rubia, J. Drach, Z. Gasztonyi, S. Górnik, X. Leleu, M. Munder, M. Offidani, N. Zojer, K. Rajangam, Y. L. Chang, J. F. San-Miguel, H. Ludwig

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

97 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)'. Together they form a unique fingerprint.

Medicine & Life Sciences